Why the study?
Current quality assessment of platelet products relies on in vitro assays analyzing platelets alone, whereas evaluating platelet physiological function under conditions resembling continuous hemostasis is ideal.
A novel in vitro system using reconstituted blood and a microchip flow-chamber (T-TAS) can quantitatively evaluate the physiological thrombus-forming ability of platelet products.
Answers are grounded in this paper and cite their sources.
May enable in vitro platelet product assessment; clinical translation and patient outcomes remain unproven.
【背景と目的】現在,血小板(Platelet:PLT)製剤の品質評価は,検査材料としてのPLTのみを分析する一連のin vitro試験で行われている.しかしながら,連続的な止血過程に近い条件下でPLT生理機能を評価することが理想的である.そこで本研究では,マイクロチャンバーを用いて,一定のせん断応力(600/s),赤血球(Red blood cell:RBC)および血漿の存在下,PLT製剤の血栓形成能を評価するin vitroシステムの開発を試みた.
No takes yet. Share an insight, caveat, or question.
Fuchizaki et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: